【摘要】 目的:探讨前列腺癌患者血清和组织中尿激酶型纤溶酶原激活物(uPA)及其受体(uPAR)的表达与临床意义。方法:应用酶联免疫法(ELISA)和免疫组织化学(SP)方法检测良性前列腺增生(BPH)患者、非骨转移前列腺癌(non-BM PCa)患者及骨转移前列腺癌(BM PCa)患者血清和组织中uPA及uPAR表达。结果:BPH患者、non-BM PCa患者和BM PCa患者血清uPA及uPAR浓度差异有统计学意义(P<0.01)。non-BM PCa患者血清uPA及uPAR浓度高于BPH患者(P<0.01),BM PCa患者高于non-BM PCa患者(P<0.01)。前列腺癌组织uPA表达阳性率83.34%,uPAR表达阳性率77.78%,良性前列腺增生组织表达阳性率为0,差异有统计学意义(P<0.01)。结论:uPA、uPA表达与PCa的发生与转移密切相关。更多还原

【Abstract】 Objective:To investigate the expression of urokinase type plasminogen activator(uPA)and its receptor(uPAR)in serum and tissue of patients with prostate cancer,and its clinical significance.Methods:Using enzyme linked immunosorbent assay(ELISA)and immunohistochemistry(SP)methods to detect expression of uPA and uPAR in serum and tissues of benign prostatic hyperplasia(BPH)patients,non bone metastasis of prostate cancer(non-BM PCa)patients and prostate cancer with bone metastasis(BM PCa)patients.Results:There was statistically different serum uPAR concentration in patients with BPH,non-BM PCa and BM PCa(P<0.01).Non-BM uPA and uPAR in serum of patients with PCa were higher than that of BPH patients(P<0.01),BM PCa patients is higher than non-BM PCa patients(P<0.01).Prostate cancer tissue uPA expression positive rate was 83.34%,the positive rate of uPAR expression was 77.78%.For benign prostatic hyperplasia tissues,the positive rate was 0,the difference was statistically significant(P<0.01).Conclusion:The expression of uPA and uPAR closely related with the occurrence and metastasis of PCa.更多还原